Trinity's haemostasis analyser gets US nod
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Destiny Max, Trinity Biotech's high-throughput haemostasis analyser. The Bray, Ireland firm immediately launched the device in the US, saying that this completes the rollout of the device in all major markets. The Destiny Max will be aimed towards university hospitals, high-throughput general hospitals, high-volume commercial laboratories and reference laboratories. Trinity estimates the worldwide high-throughput haemostasis market at $500m per annum. It CE marked the analyser in December 2008.